Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

BACKGROUND: Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM and mRCC patients. The efficacy an...

Full description

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Buchbinder, Elizabeth I., Dutcher, Janice P., Daniels, Gregory A., Curti, Brendan D., Patel, Sapna P., Holtan, Shernan G., Miletello, Gerald P., Fishman, Mayer N., Gonzalez, Rene, Clark, Joseph I., Richart, John M., Lao, Christopher D., Tykodi, Scott S., Silk, Ann W., McDermott, David F.
Format: Artigo
Language:Inglês
Published: BioMed Central 2019
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6380045/
https://ncbi.nlm.nih.gov/pubmed/30777131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0522-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items